On November 1, 2017 Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), reported that abstracts regarding the Company’s allogeneic, off-the-shelf, CAR T product candidates have been accepted for presentation at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Cellectis, NOV 1, 2017, View Source [SID1234521419]). The meeting will be held from December 9 to 12, 2017 in Atlanta, GA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral presentations:
UCARTCS1 product candidate targeting Multiple Myeloma
502. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma
Abstract: View Source
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutic Strategies in Multiple Myeloma Session
Sunday, December 10, 2017 at 5:15 PM
Location: Bldg B, Lvl 3, B308-B309 (Georgia World Congress Center)
Rohit Mathur1, Zheng Zhang1, Jin He1, Roman Galetto2, Agnès Gouble2, Isabelle Chion-Sotinel2, Stéphanie Filipe2, Annabelle Gariboldi2, Tanooha Veeramachaneni1, Elisabet E. Manasanch1, Sheeba K. Thomas1, Hans C. Lee1, Krina K. Patel1, Donna M. Weber1, R. Eric Davis1, Robert Z. Orlowski1, Julianne Smith3, Jing Yang1, and Sattva S. Neelapu1
1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
2Cellectis SA, 8 rue de la croix Jarry, 75013 Paris, France
3Cellectis Inc, 430 East 29th Street, 10016 New York, NY, USA
UCART22 product candidate targeting B-Acute Lymphoblastic Leukemia
808. Pre-clinical Activity of Allogeneic Anti-CD22 CAR T-Cells for the Treatment of B-cell Acute Lymphoblastic Leukemia
Abstract: View Source
Session Name: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR-T Cell Immunotherapy
Monday, December 11, 2017: 5:15 PM
Location: Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)
Julia Wells PhD1, Tianyu Cai, PhD1, Cécile Schiffer-Manniou PhD2, Stéphanie Filipe, PhD2, Agnès Gouble, PhD2, Roman Galetto, PhD2, Nitin Jain MD1, Elias Jabbour MD1, Julianne SmithPhD3 and Marina Konopleva, MD, PhD1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Cellectis SA, Paris, France
3Cellectis Inc, New York, NY
Poster Presentation:
UCART123 product candidate targeting Blastic Plasmacytoid Dendritic Cell Neoplasm
2625. Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Abstract: View Source
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Sunday, December 10, 2017 from 6:00 PM to 8:00 PM
Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
Tianyu Cai1, Roman Galetto2, Agnès Gouble2, Julianne Smith3, Antonio Cavazos1, Lina Han1, Qi Zhang1, Vinitha Kuruvilla1, Sergej Konoplev4, Sattva S. Neelapu5, Andrew A. Lane6, Monica Guzman7, Hagop Kantarjian1, Naveen Pemmaraju1, Marina Konopleva1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Cellectis SA, Paris, France
3Cellectis Inc, New York, NY
4Department of Hematopathology, The University of MD Anderson Cancer Center, Houston, TX
5Department of Lymphoma and Myeloma, The University of MD Anderson Cancer Center, Houston, TX
6Dana-Farber Cancer Institute, Boston
7Department of Medicine, Weill Cornell Medical College, New York, NY